Purpose. The association between serum lipids and bone mineral density (BMD) has been investigated previously but, up to now, these relationships have not yet been described in spinal cord injury (SCI). We tried to assess the correlation between serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) and BMD in male subjects with SCI. Methods. Dual-energy X-ray absorptiometry (DXA) was used to assess BMD in femoral neck, trochanter, intertrochanteric zone, and lumbar vertebras. Blood samples were taken to measure serums lipids and bone biomarkers including osteocalcin, cross-linked type I collagen (CTX), and bone alkaline phosphatase (BALP). Partial correlation analysis was used to evaluate the relationships between mentioned measurements after adjustment for weight and age. Results. We found a positive correlation between HDL and femoral neck BMD ( : 0.004, ). HDL was negatively correlated with osteocalcin ( : 0.017, ) which was not in consistency with its relationship with BMD. TC and LDL were not related to CTX, BALP and BMD. Conclusion. This study does not support a strong association between serum lipids and BMD in subjects with SCI. Moreover it seems that positive association between HDL and BMD is not mediated through increased bone formation. 1. Introduction Existence of a probable relationship between lipid profile and bone mineral density (BMD) was initially derived from reported results on statins’ positive effect on BMD [1, 2]. Various studies have supported the promising influence of statins (the HMG co-A reductase inhibitors) on reduction of fractures along with increased BMD [3, 4]. The assumption of relationship between lipids and BMD was tested in two cohort studies and showed a significant positive association between BMD and low density lipoprotein (LDL) and total triglyceride (TG) while it was negatively correlated with high density lipoprotein (HDL) [5]. However some other literatures showed no relationship between lipid profile and BMD [6]. Most of these studies were on healthy individuals. Spinal cord injury (SCI) is a severe medical condition which restricts physical activities tremendously [7]. Along with immobility, it is associated with some changes in lipid profile [8–10]. In this regard, de Groot et al. demonstrated decreased TC and elevated HDL during and one year after rehabilitation; however these patients may also experience increased levels of TC and LDL after discharge [8]. The study of de Groot also revealed the effect of age in subjects with SCI since higher
References
[1]
P. S. Wang, D. H. Solomon, H. Mogun, and J. Avorn, “HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients,” The Journal of the American Medical Association, vol. 283, no. 24, pp. 3211–3216, 2000.
[2]
G. Mundy, R. Garrett, S. Harris et al., “Stimulation of bone formation in vitro and in rodents by statins,” Science, vol. 286, no. 5446, pp. 1946–1949, 1999.
[3]
C. R. Meier, R. G. Schlienger, M. E. Kraenzlin, B. Schlegel, and H. Jick, “HMG-CoA reductase inhibitors and the risk of fractures,” The Journal of the American Medical Association, vol. 283, no. 24, pp. 3205–3210, 2000.
[4]
M. W. C. J. Schoofs, M. C. J. M. Sturkenboom, M. van der Klift, A. Hofman, H. A. P. Pols, and B. H. C. Stricker, “HMG-CoA reductase inhibitors and the risk of vertebral fracture,” Journal of Bone and Mineral Research, vol. 19, no. 9, pp. 1525–1530, 2004.
[5]
S. Adami, V. Braga, M. Zamboni et al., “Relationship between lipids and bone mass in 2 cohorts of healthy women and men,” Calcified Tissue International, vol. 74, no. 2, pp. 136–142, 2004.
[6]
D. H. Solomon, J. Avorn, C. F. Canning, and P. S. Wang, “Lipid levels and bone mineral density,” The American Journal of Medicine, vol. 118, no. 12, pp. 1414–e5, 2005.
[7]
M. Midha, J. K. Schmitt, and M. Sclater, “Exercise effect with the wheelchair aerobic fitness trainer on conditioning and metabolic function in disabled persons: a pilot study,” Archives of Physical Medicine and Rehabilitation, vol. 80, no. 3, pp. 258–261, 1999.
[8]
S. de Groot, A. J. Dallmeijer, M. W. Post, E. L. Angenot, R. J. van den Berg-Emons, and L. H. van der Woude, “Prospective analysis of lipid profiles in persons with a spinal cord injury during and 1 year after inpatient rehabilitation,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 3, pp. 531–537, 2008.
[9]
P. Y. Wong, Y. C. Wang, N. K. Chu, F. T. Tang, and M. K. Wong, “Body weight, serum uric acid and lipid profile one year after spinal cord injury,” Chang Gung medical journal, vol. 24, no. 9, pp. 569–575, 2001.
[10]
W. A. Bauman, R. H. Adkins, A. M. Spungen, P. Maloney, R. Gambino, and R. L. Waters, “Ethnicity effect on the serum lipid profile in persons with spinal cord injury,” Archives of Physical Medicine and Rehabilitation, vol. 79, no. 2, pp. 176–180, 1998.
[11]
R. A. Battaglino, A. A. Lazzari, E. Garshick, and L. R. Morse, “Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies,” Current Osteoporosis Reports, vol. 10, no. 4, pp. 278–285, 2012.
[12]
C. Fattal, D. Mariano-Goulart, E. Thomas, H. Rouays-Mabit, C. Verollet, and L. Maimoun, “Osteoporosis in persons with spinal cord injury: the need for a targeted therapeutic education,” Archives of Physical Medicine and Rehabilitation, vol. 92, no. 1, pp. 59–67, 2011.
[13]
C. Charmetant, V. Phaner, A. Condemine, and P. Calmels, “Diagnosis and treatment of osteoporosis in spinal cord injury patients: a literature review,” Annals of Physical and Rehabilitation Medicine, vol. 53, no. 10, pp. 655–668, 2010.
[14]
S. Jiang, L. Jiang, and L. Dai, “Mechanisms of osteoporosis in spinal cord injury,” Clinical Endocrinology, vol. 65, no. 5, pp. 555–565, 2006.
[15]
H. Sabour, A. Norouzi Javidan, S. Latifi et al., “Bone biomarkers in patients with chronic traumatic spinal cord injury,” The Spine Journal, vol. 14, no. 7, pp. 1132–1138, 2014.
[16]
F. Sivas, E. Alemdaro？lu, E. Elverici, T. Kulu？, and K. ？zoran, “Serum lipid profile: its relationship with osteoporotic vertebrae fractures and bone mineral density in Turkish postmenopausal women,” Rheumatology International, vol. 29, no. 8, pp. 885–890, 2009.
[17]
R. A. Brownbill and J. Z. Ilich, “Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women,” Journal of Women's Health, vol. 15, no. 3, pp. 261–270, 2006.
[18]
P. Orozco, “Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women,” European Journal of Epidemiology, vol. 19, no. 12, pp. 1105–1112, 2004.
[19]
S. Ba？？？, G. ？ahin, C. Aybay, and A. Karag？z, “Bone metabolism in patients with spinal cord injury,” Turkish Journal of Rheumatology, vol. 17, pp. 168–173, 2002.
[20]
A. El Maghraoui and C. Roux, “DXA scanning in clinical practice,” QJM, vol. 101, no. 8, pp. 605–617, 2008.
[21]
K. J. Rothman and S. Greenland, Modern Epidemiology, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2nd edition, 1998.
[22]
J. L. Hernández, J. M. Olmos, G. Roma？a et al., “Bone mineral density in statin users: a population-based analysis from a Spanish cohort,” Journal of Bone and Mineral Metabolism, vol. 32, no. 2, pp. 184–191, 2014.
[23]
S. Chuengsamarn, S. Rattanamongkoulgul, S. Suwanwalaikorn, S. Wattanasirichaigoon, and L. Kaufman, “Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia,” Bone, vol. 46, no. 4, pp. 1011–1015, 2010.
[24]
Y. Wada, Y. Nakamura, and H. Koshiyama, “Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes,” Archives of Internal Medicine, vol. 160, no. 18, p. 2865, 2000.
[25]
J. A. Pasco, M. A. Kotowicz, M. J. Henry, K. M. Sanders, and G. C. Nicholson, “Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study,” Archives of Internal Medicine, vol. 162, no. 5, pp. 537–540, 2002.
[26]
G. V. R. Prasad, R. Chiu, M. M. Nash, and J. S. Zaltzman, “Statin use and bone mineral density in renal transplant recipients,” American Journal of Transplantation, vol. 3, no. 10, pp. 1320–1321, 2003.
[27]
E. J. Samelson, L. A. Cupples, M. T. Hannan et al., “Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study,” Bone, vol. 34, no. 3, pp. 557–561, 2004.
[28]
E. M. Dennison, H. E. Syddall, A. Aihie Sayer, H. J. Martin, and C. Cooper, “Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study,” QJM, vol. 100, no. 5, pp. 297–303, 2007.
[29]
W. A. Bauman, A. M. Spungen, Y. G. Zhong, J. L. Rothstein, C. Petry, and S. K. Gordon, “Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury,” Paraplegia, vol. 30, no. 10, pp. 697–703, 1992.
[30]
G. Brenes, S. Dearwater, R. Shapera, R. E. LaPorte, and E. Collins, “High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients,” Archives of Physical Medicine and Rehabilitation, vol. 67, no. 7, pp. 445–450, 1986.
[31]
H. Krum, L. G. Howes, D. J. Brown et al., “Risk factors for cardiovascular disease in chronic spinal cord injury patients,” Paraplegia, vol. 30, no. 6, pp. 381–388, 1992.
[32]
L. B. Tankó, Y. Z. Bagger, S. B. Nielsen, and C. Christiansen, “Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?” Bone, vol. 32, no. 1, pp. 8–14, 2003.
[33]
L. Y. Wu, T. C. Yang, S. W. Kuo et al., “Correlation between bone mineral density and plasma lipids in Taiwan,” Endocrine Research, vol. 29, no. 3, pp. 317–325, 2003.
[34]
F. Parhami, N. Mody, N. Gharavi, A. J. Ballard, Y. Tintut, and L. L. Demer, “Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells,” Journal of Bone and Mineral Research, vol. 17, no. 11, pp. 1997–2003, 2002.
[35]
P. Garnero, M. Ferreras, M. A. Karsdal et al., “The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation,” Journal of Bone and Mineral Research, vol. 18, no. 5, pp. 859–867, 2003.
[36]
H. N. Rosen, A. C. Moses, J. Garber et al., “Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy,” Calcified Tissue International, vol. 66, no. 2, pp. 100–103, 2000.
[37]
J. B. Lian and C. M. Gundberg, “Osteocalcin. Biochemical considerations and clinical applications,” Clinical Orthopaedics and Related Research, no. 226, pp. 267–291, 1988.
[38]
P. Pliatsika, A. Antoniou, A. Alexandrou et al., “Serum lipid levels and bone mineral density in Greek postmenopausal women,” Gynecological Endocrinology, vol. 28, no. 8, pp. 655–660, 2012.
